Different Response to Immunotherapy According to Melanoma Histologic Subtype. Issue 2 (February 2022)

• Record Type: Journal Article
• Authors: Pala, Laura; Conforti, Fabio; Pagan, Eleonora; Bagnardi, Vincenzo; De Pas, Tommaso M.; Mazzarol, Giovanni; Barberis, Massimo; Pennacchioli, Elisabetta; Orsolini, Gianmarco; Prestianni, Pierpaolo; Zagami, Paola; Nicolo', Eleonora; Patanè, Damiano; Saponara, Maristella; Queirolo, Paola
• Is Part Of: Journal of immunotherapy. Volume 45:Issue 2(2022)
• Publication Date: 2022-02
• Subjects: melanoma -- histologic subtype -- immunotherapy; Immunotherapy -- Periodicals; Immunotherapy -- Periodicals; Neoplasms -- therapy -- Periodicals; Electronic journals; Electronic journals; 615.37
• DOI: 10.1097/CJI.0000000000000403
• Languages: English
• ISSNs: 1524-9557

Abstract

Abstract : Superficial spreading melanoma (SSM) and nodular melanoma (NM) are the most common melanoma histologic subtypes and are characterized by different biological features. We retrospectively analyzed all consecutive patients with advanced melanoma, treated with anti-PD-1 and/or anti-CTLA-4 at our center, with data available on primary tumor subtype. The primary objective was to assess the association between histologic subtype and patients' outcomes. In addition, we analyzed whole-exome and whole-transcriptome sequencing data of a cohort of advanced melanoma to identify genes and related pathways, characterized by significant differences between NMs and SSMs. Twenty-one patients with NM and 39 with SSM, treated with anti-PD-1(53/60) as monotherapy or combined with anti-CTLA-4 (7/60), were analyzed. All known clinical-pathologic prognostic factors were well balanced between NM and SSM groups, except for the ECOG-PS score. The overall response rate was 52.4% (95% confidence interval, 29.8–74.3) in the NMs group versus 20.5% (9.3–36.5) in the SSMs group ( P -value=0.02). The median progression-free survival and overall survival were, respectively, 13.9 and 44.5 months in the NMs group versus only 3.2 and 12 months in SSMs group (progression-free survival P -value=0.032; overall survival P -value=0.002). Multivariable analysis adjusting for the ECOG-PS, confirmed similar results. Whole-exome and whole-transcriptome data of 28 NMs and 21 SSMs were analyzed. No significant differences were observed in terms of both TMB and frequency of mutation in any gene. A total of 266 genes were overexpressed in NMs as compared with SSMs, and enrichment-analysis revealed a significant enrichment (false discovery rate<0.05) of genes belonging to immune-related pathways involved in antigens presentation mechanisms, response to interferon gamma and neutrophil activation. We provided clinical evidences suggesting a relevant association between melanoma histologic subtype and response to immunotherapy. Abstract : Supplemental Digital Content is available in the text.